Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer

Inclusion Criteria: * Female subjects 55 to 80 years with histologically or cytologically documented primary intraductal or lobular invasive breast cancer that meets the following criteria: * T2, N0 or N1, M0. * Primary tumour clinically determined to be 2 to 5 cm in the greatest dimension. * Laboratory documentation of positive oestrogen receptor (ER+) status in at least 10% of the tumour cells. * Laboratory documentation of HER-2 negative status. Postmenopausal defined as * no spontaneous menses for a total of 2 years * amenorrheic for at least 12 months with serum oestrogen level \<30 pg/mL, and both luteinising hormone (LH)/follicle stimulating hormone (FSH) \>20 IU/L, chemotherapy-induced amenorrhoea for at least 12 months * bilateral oophorectomy, or radiation castration and amenorrhoeic for at least 3 months. Eastern Cooperative Oncology Group (ECOG) performance status ≤2. Exclusion Criteria: * Has locally advanced breast cancer that is considered non-operable without neoadjuvant therapy. * Has evidence of metastatic disease * as a diagnosis of inflammatory breast cancer * Has ductal carcinoma in situ